WIRB - AN OPEN-LABEL, MULTIPLE-DOSE, CROSS-OVER STUDY TO EVALUATE: HIV

WIRB - 一项开放标签、多剂量、交叉研究来评估：HIV

• 批准号: 8167327
• 负责人: Steven L. Zeichner
• 金额: $ 0.31万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-20 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167327
• 关键词: 18 year old; Adherence; Child; Computer Retrieval of Information on Scientific Projects Database; Cross-Over Studies; Dose; Drug Formulations; Drug Kinetics; Funding; Grant; HIV; Institution; Marketing; Nevirapine; Oral; Regimen; Relative (related person); Research; Research Personnel; Resources; Source; Suspension substance; Suspensions; Tablets; Therapeutic; United States National Institutes of Health; Viral; antiretroviral therapy; compliance behavior; improved; open label; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective is to establish the pharmacokinetic profile at steady state of nevirapine XR in children from e3 to 18 years of age. Adherence is a major factor in determining the degree of viral suppression achieved in response to antiretroviral therapy. An extended release formulation of nevirapine may offer a meaningful therapeutic benefit, relative to marketed nevirapine oral suspension and 200 mg BID tablets by facilitating a once daily dosing regimen, thus improving treatment compliance. In addition, nevirapine extended release could demonstrate improved tolerability in comparison with the marketed suspension.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 主要目标是建立奈韦拉平 XR 稳态下的药代动力学特征 e3 至 18 岁的儿童。依从性是决定依从程度的重要因素 抗逆转录病毒治疗产生的病毒抑制。延长发布 相对于市售的奈韦拉平制剂可能会提供有意义的治疗益处 奈韦拉平口服混悬液和 200 mg BID 片剂，通过促进每日一次的给药方案， 从而提高治疗依从性。此外，奈韦拉平缓释剂还可以 与市售悬浮液相比，表现出更好的耐受性。